Clinical Trial Update: 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC [Phase 2]

View source ↗

Summary

This Phase 2 trial assesses dovitinib as a first-line treatment for clear cell renal cell carcinoma. It also analyzes correlations between genetic changes and t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Auckland District Health Board | Conditions: Clear Cell Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN